Current Report Filing (8-k)
January 21 2020 - 8:36AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): January 6, 2020
E-QURE
CORP.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 000-54862
Delaware
|
|
47-1691054
|
(State
or other Jurisdiction
of
Incorporation or Organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
20
West 64th Street, Suite 39G, New York, NY
|
|
10023
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: + (972) 54-422-7777
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(g) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.00001
|
|
EQUR
|
|
OTCQB
|
Item
8.01 Other Events.
E-Qure
Corp., a Delaware corporation, OTCQB: EQUR (the “Company”), a medical device Company, reported today the following
material updates regarding Bioelectrical Signal Therapy device (“BST Device) developed for the treatment of wounds
via electrical stimulation, which is believed to result in accelerated wound healing by imitating the natural electrical current
that occurs in injured skin on the human body. Our BST Device stimulates renewed blood flow and oxygen in order to induce local
cell regeneration and therefore promote wound healing.
1.
The Company has been granted with the Helsinki committee approval of Clalit Health Services Organization, Israel’s largest
HMO, and the Israeli Ministry of Health (MOH) to launch a Randomized Control Study (RCT) on 60-100 patients in order to assess
the efficacy of the BST Device on diabetic foot patients. The study will be performed in 3-5 sites including leading clinics and
hospitals in Israel. The Company intends to enroll the first patients to the study during the next 2-3 weeks and expects the trial
to be conducted for 12-18 months until completion.
2.
The Company has concluded a 35-wound, one arm clinical pilot, treating recalcitrant wounds in a leading wound clinic in Tel Aviv
Israel, with 78% of the treated wounds completely healed within 20 weeks (Avg. wound duration at the base was 8 months) and an
additional 16% of the treated wounds reaching wound area reduction of greater than 75%. Only 6% of the patients had no substantial
positive clinical effect.
3.
The Company recently filed a provisional patent with United States Patent and Trademark Office for the purpose of protecting the
main features of our proprietary unique electrical healing signal BST Device.
4.
The Company’s distributor in Colombia, TekMedica SAS, has successfully concluded a clinical pilot study at the Hospital
de la Samaritana in Bogota, Colombia. Starting in January 2020, Colsanitas, a leading Colombian HMO/Health insurance provider
and operator of comprehensive healthcare services in Colombia and a member of the Sanitas group worldwide, will commence a clinical
pilot study which is expected to be concluded by the end of the first half of 2020. If positive results are achieved, similar
to those achieved in the Tel Aviv clinical trials, the Company believes that it will contribute to the penetration of the BST
device treatment with Colsanitas health services in Colombia.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
E-QURE
CORP.
|
|
|
|
|
|
/s/:
Ohad Goren
|
|
Name:
|
Ohad
Goren
|
|
Title:
|
Chief
Executive Officer
|
|
Dated:
|
January
21, 2020
|
|